# A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Study · id `cardio:ct-nct05952856` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05952856](<https://clinicaltrials.gov/study/NCT05952856>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05952856

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2912 participants.

## Technical summary

Registry record NCT05952856. Randomized; triple masking; primary purpose treatment. Start 2023-08-10 (actual); primary completion 2025-07-28 (actual). Results posted on 2026-08-06.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2912 participants (enrolled count; ClinicalTrials.gov record NCT05952856, source copy `cardio:ctgov-nct05952856-2026-09-24`, retrieved 2026-10-31)
- Started: 2023-08-10 (actual) (ClinicalTrials.gov record NCT05952856, source copy `cardio:ctgov-nct05952856-2026-09-24`, retrieved 2026-10-31)
- Primary completion: 2025-07-28 (actual) (ClinicalTrials.gov record NCT05952856, source copy `cardio:ctgov-nct05952856-2026-09-24`, retrieved 2026-10-31)
- Completion: 2025-07-28 (actual) (ClinicalTrials.gov record NCT05952856, source copy `cardio:ctgov-nct05952856-2026-09-24`, retrieved 2026-10-31)
- Results first posted: 2026-08-06 (ClinicalTrials.gov record NCT05952856, source copy `cardio:ctgov-nct05952856-2026-09-24`, retrieved 2026-10-31)
- Countries: United States; Argentina; China; Colombia; Germany; Israel; Italy; Japan; Mexico; South Africa; South Korea; Spain; Taiwan; Türkiye (ClinicalTrials.gov record NCT05952856, source copy `cardio:ctgov-nct05952856-2026-09-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05952856-2026-09-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
- Condition: Hypercholesterolemia
- Condition: Familial Hypercholesterolemia
- Intervention (Drug): Enlicitide Decanoate
- Intervention (Drug): Placebo
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide (`cardio:pubmed-41879224`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 53895bb22e72143c4122cee4d4a82689353d0fc7077c8c0a803f8dd8eb6573e5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
